Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Slides:

Advertisements

Similar presentations

The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.

Advertisements

Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.

What Is the Role for Analyses of Administrative Data in Assessing Drug Safety in Post-Market Commitment (PMC) Studies? Cathy W. Critchlow, PhD Global Epidemiology,

Agency for Healthcare Research and Quality (AHRQ)

Assessment of Harm based on our best available evidences The EBM workshop A.A.Haghdoost, MD; PhD of Epidemiology

Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)

Julianne Gee, MPH Immunization Safety Office

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Study Designs in Epidemiologic

Introduction to Epidemiology

1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.

Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.

Pharmacoepidemiology: Goals and Methods Sean Hennessy, PharmD, PhD Assistant Professor of Epidemiology & Pharmacology Center for Clinical Epidemiology.

Surveillance. Definition Continuous and systematic process of collection, analysis, interpretation, and dissemination of descriptive information for monitoring.

Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,

Interpreting Adverse Signals in Diabetes Drug Development Programs Featured Article: Clifford J. Bailey, Ph.D. Diabetes Care Volume 36: 1-9 July, 2013.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Dr K N Prasad MD., DNB Community Medicine

As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,

Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.

1Stopeck A et al. Proc SABCS 2010;Abstract P

DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.

Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.

POSTMARKETING ADVERSE DRUG EXPERIENCE INSPECTIONAL PROGRAM CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.

Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

CHP400: Community Health Program- lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Case Control Studies Present: Disease Past:

Life Sciences Research Office (LSRO) Evaluating Adverse Event Reporting Systems for Dietary Supplements January 30-31, 2003 “Open Portion of Meeting”

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Study Designs in Epidemiologic

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.

1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

Using the FDA’s Adverse Event Reporting System (AERS) in Postmarketing Surveillance Joyce P. Weaver, Pharm.D., BCPS Division of Drug Risk Evaluation Office.

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

Causal relationships, bias, and research designs Professor Anthony DiGirolamo.

1 TNF Blocker Safety: Lymphoma and Liver Failure Tim Coté MD MPH, Chief, Therapeutics & Blood Safety Branch, DE/OBE/CBER/FDA March 4, 2003.

FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.

Overview of Study Designs. Study Designs Experimental Randomized Controlled Trial Group Randomized Trial Observational Descriptive Analytical Cross-sectional.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

Good Pharmacovigilance Practices

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

Surveillance Key Points Dr. Oswaldo S. Medina Gómez.

Macrolide Antibiotics and Torsade de Pointes Postmarketing Analysis

Signal identification and development I.Ralph Edwards.

Descriptive study design

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

CCEB October 30 David J. Margolis MD PhD Associate Professor of Dermatology and Epidemiology Center for Clinical Epidemiology and Biostatistics University.

Osteonecrosis of the Jaws in Myeloma BRIAN G.M. DURIE, M.D., Michael Katz, Jason McCoy, MS and John Crowley, PhD Hematology/Oncology, Cedars-Sinai Outpatient.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

Lesson 4Page 1 of 27 Lesson 4 Sources of Routinely Collected Data for Surveillance.

Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.

REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.

1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.

Postmarketing Pharmacovigilance English D. Willis, MD Clinical Risk Management Merck Research Laboratories June 1, 2012.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

Measures of disease frequency Simon Thornley. Measures of Effect and Disease Frequency Aims – To define and describe the uses of common epidemiological.

Research Activities at The Boston Collaborative Drug Surveillance Program; Boston University School of Public Health Susan Jick Professor of Epidemiology.

Present: Disease Past: Exposure

Mortality and Antithrombotics: Focus on FAERS Repository

Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.

Presentation transcript:

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol Pamer, R.Ph. Carolyn McCloskey, M.D., M.P.H. March 4, 2005

2 Outline Overview of Adverse Event Reporting System (AERS) and safety signal review Summary of pamidronate & zoledronic acid cases of osteonecrosis of the jaw (ONJ) Issues concerning review of AERS reports Considerations for future studies of ONJ

3 AERS (Adverse Event Reporting System) FDA has maintained a database of spontaneous reporting system case reports since 1969 Number of modifications made, including coding dictionary, search interface, and expanded database capacity

4 Factors Affecting Reporting Nature of the adverse event Type of drug product and indication Length of time on market Media attention Extent and quality of manufacturer’s surveillance system Prescription or over-the-counter drug status Reporting regulations

5 Evaluation of Cases General Approach Adverse event occurrence in expected time Absence of symptoms prior to exposure Positive dechallenge or rechallenge Consistent with pharmacological effects Consistent with known effects in the class Support from pre-clinical studies, clinical trials Absence of alternative explanations

6 Limitations of Spontaneous Reports Passive surveillance –Underreporting occurs and is variable from drug to drug and over time Reporting bias exists Quality of the reports is variable and often incomplete Duplicate reporting occurs Can not reliably estimate incidence rates of events; numerator uncertain, denominator can only be projected

7 Best Applications of AERS Safety signal generation and descriptive case series Events that are linked to specific diagnoses Events with a serious outcome that rarely occur in an untreated population Events with a short-to-moderate latency period following exposure

8 Pamidronate & Zoledronic Acid

9 Spontaneous Reports Pamidronate & Zoledronic Acid Case series of postmarketing spontaneous reports Drugs: Pamidronate, Zoledronic acid Database search terms related to diagnosis of osteonecrosis/osteomyelitis Cut-off date: January 13, 2005 Jaw involvement only, consistent w/ONJ

10 Spontaneous Reports of ONJ General Characteristics

11 Spontaneous Reports of ONJ (cont.) General Characteristics

12 Difficulties in Assessing Cases Increased reporting likely due to DHP letter, publications, presentations, Confounding factors present in many Assessment of dechallenge, rechallenge confounded Determining time to onset of event

13 Confounding Factors Most reports listed one or more of the following: –Drugs : corticosteroids, other bisphosphonates, thalidomide, cancer chemotherapy –Procedures: tooth extractions –Medical conditions: cancer Missing information in others

14 Limitations of Dechallenge Assessment ONJ did not quickly resolve, regardless of therapies and drug dechallenge Most patients had continuing symptoms as of last follow-up obtained Multiple therapeutic interventions received by most patients Persistence of bisphosphonates in bone

15 Determining Time to Onset Many patients developed symptoms after dental procedure (tooth extraction) w/lesion that did not heal Case series only included diagnosed ONJ, not symptoms alone (e.g., jaw pain, tooth loss) In many cases, information on early symptoms was missing

16 Epidemiological Perspective

17 Challenges of Studying ONJ ONJ rare event –Difficult to get background rates in general population; difficult to monitor trends Difficulty in identifying cases with ONJ in databases –No specific ICD-9 code Difficulty obtaining data on drug exposure Lack of suitable control/comparison groups

18 Potential Study Data Sources Oncology Clinics –IV Bisphosphonate-Exposed Population Dentists & Oral Surgeons –Cases of ONJ Registry of all cases identified in different settings

19 Considerations for Future Studies Limited utility of available data –Pharmacoepidemiological or postmarketing surveillance data Randomized, controlled trial data may be superior to data from these sources Use of registry to collect cases might be explored

20 Conclusion Cases of ONJ reported in association with these drugs represent a highly plausible signal –Site specificity –Number of reports submitted to AERS –Temporal association –Serious outcome To identify contributing risk factors other studies are necessary

21 Acknowledgements Mark Avigan, M.D., C.M. Jennie Chang, Pharm.D. Lanh Green, Pharm.D., M.P.H. Mary Willy, Ph.D.